What do systematic reviews say?

Budesonide 9 mg vs steroids

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.57 [0.18, 1.84]
  5 studies · 522 participants
  Low

Budesonide 9 mg vs mesalamine

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with mesalamine (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.43 [0.18, 1.03]
  2 studies · 489 participants
  Low

Budesonide 9 mg vs placebo

Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.14 [0.46, 2.79]
  3 studies · 379 participants
  Low

Budesonide 9 mg vs placebo

Budesonide 9 mg showed no clear difference in corticosteroid related adverse events compared with placebo (moderate certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.97 [0.76, 1.23]
  3 studies · 384 participants
  Moderate

Budesonide vs mesalamine

Budesonide showed no clear difference in serious adverse events compared with mesalamine (low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 0.75 [0.17, 3.28]
  1 study · 254 participants
  Low

Budesonide vs mesalamine

Budesonide showed no clear difference in adverse events Gross 2011 compared with mesalamine (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.05 [0.73, 1.5]
  1 study · 343 participants
  Moderate

Budesonide vs placebo

Budesonide showed no clear difference in adverse events compared with placebo (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 1.18 [0.92, 1.51]
  5 studies · 290 participants
  Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.69 [0.43, 1.1]
  1 study · 55 participants
  Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide showed no clear difference in adverse events compared with mesalazine (low certainty).

• Interventions for treating lymphocytic colitis 2017 · Cochrane Headline outcomes only
  RR 0.67 [0.12, 3.59]
  1 study · 42 participants
  Low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide showed no clear difference in serious adverse events compared with mesalazine (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.12 [0.01, 2.21]
  1 study · 55 participants
  Low

Budesonide vs placebo

It is very uncertain whether budesonide changes serious adverse events compared with placebo (very low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 1.11 [0.15, 8.01]
  4 studies · 175 participants
  Very low

Budesonide MMX® 6 mg vs placebo

It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.13 [0.97, 1.32]
  2 studies · 512 participants
  Very low

Budesonide MMX® 9 mg vs Entocort EC 9mg

Budesonide MMX® 9 mg showed no clear difference in adverse events compared with entocort EC 9mg (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.01 [0.81, 1.26]
  1 study · 254 participants
  Moderate

Budesonide MMX® 9 mg vs placebo

Budesonide MMX® 9 mg showed no clear difference in adverse events compared with placebo (moderate certainty).

• Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 1.09 [0.95, 1.26]
  3 studies · 971 participants
  Moderate

Budesonide vs placebo

It is very uncertain whether budesonide changes withdrawals due to adverse events compared with placebo (very low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.43, 2.17]
  5 studies · 290 participants
  Very low

Budesonide vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Budesonide showed no clear difference in withdrawals due to adverse events compared with mesalazine (low certainty).

• Interventions for treating collagenous colitis 2017 · Cochrane Headline outcomes only
  RR 0.09 [0.01, 1.65]
  1 study · 55 participants
  Low

Budesonide 3 mg vs placebo

Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.66 [0.11, 3.8]
  1 study · 133 participants
  Low

Budesonide 3 mg vs placebo

Budesonide 3 mg showed no clear difference in corticosteroid related adverse events compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.58 [0.29, 1.17]
  1 study · 133 participants
  Low

Budesonide vs placebo

• Interventions for preventing high altitude illness: Part 1. Commonly‐used classes of drugs 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Very low

Budesonide 15 mg vs placebo

Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

• Budesonide for induction of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.55 [0.45, 5.34]
  2 studies · 181 participants
  Low